Stocks Health care EIKN
NASDAQ · Health careEikon Therapeutics, Inc. (EIKN)
At June 30, 2026 it held $142.6M in cash. Its latest periodic report to the SEC is the quarterly report (10-Q) filed on August 13, 2026.
Key facts about Eikon Therapeutics, Inc.
- Net worth
- Eikon Therapeutics, Inc. has a market value (market cap) of $329.9M at the latest share price. A company's "net worth" usually means this market value or the shareholders' equity on its balance sheet.
- Latest report
- The latest periodic report (quarterly report, 10-Q) was filed with the SEC on August 13, 2026 and covers the period to June 30, 2026. Open on SEC EDGAR
- Next earnings report
- Eikon Therapeutics, Inc.'s next report was expected around October 20, 2026 and is not on file with the SEC yet.
What Eikon Therapeutics, Inc. does
Eikon Therapeutics, Inc. is registered with the SEC under industry code SIC 2836 (Biological Products, (No Diagnostic Substances)). Its shares trade on NASDAQ under the ticker EIKN.
Earnings: every quarter and the next report date
Latest SEC filings
What Eikon Therapeutics, Inc. has filed recently, newest first. Each links to the original document on SEC EDGAR.
- October 26, 2026
- October 23, 2026
- October 7, 2026Passive stake changed SCHEDULE 13G/A
- October 2, 2026Passive stake changed SCHEDULE 13G/A
- August 14, 2026
- August 13, 2026
- August 13, 2026
- August 6, 2026Passive stake changed SCHEDULE 13G/A
- August 3, 2026
- June 10, 2026
Insider trades
What the people running Eikon Therapeutics, Inc. did with its shares, from the Form 4 filings they must send the SEC within two business days.
Insiders bought $1M worth of shares on the open market in the last 90 days and sold none.
| Date | Insider | What | Shares | Value |
|---|---|---|---|---|
| September 3, 2026 | Column Group IV GP, LP10% owner | Boughtindirect | 89,200 | $1M |
| February 6, 2026 | Perlmutter Roger MSee remarks, Director | Exercised optionsindirect | 284,857 | - |
| February 6, 2026 | Column Group IV GP, LP10% owner | Exercised optionsindirect | 1,296,629 | - |
| February 6, 2026 | Column Group IV GP, LP10% owner | Exercised optionsindirect | 1,403,568 | - |
| February 6, 2026 | Column Group IV GP, LP10% owner | Exercised optionsindirect | 110,928 | - |
| February 6, 2026 | Column Group IV GP, LP10% owner | Exercised optionsindirect | 44,249 | - |
| February 6, 2026 | Column Group IV GP, LP10% owner | Exercised optionsindirect | 47,898 | - |
| February 6, 2026 | Column Group IV GP, LP10% owner | Exercised optionsindirect | 3,785 | - |
Who owns EIKN
Three views from three kinds of SEC filings, each with its own date. They overlap and are not added up.
5% holders
| Holder | Of class | Filed |
|---|---|---|
| Tim Kutzkey13D, may seek influence with 7 related filers | 11.6% | February 12, 2026 |
| Fmr LLC13G, passive with 1 related filers | 9.2% | August 6, 2026 |
| James B. Tananbaum13G, passive with 8 related filers | 7.7% | February 11, 2026 |
| BlackRock Portfolio Management LLC13G, passive | 5.5% | April 29, 2026 |
| Perlmutter Roger M13G, passive | 5.2% | May 13, 2026 |
| Innovation Endeavors III LP13G, passive with 5 related filers | 5% | May 15, 2026 |
Largest institutional holders
Positions that investment managers reported on Form 13F for the quarter ended June 30, 2026, largest first, with the change on the quarter ended March 31, 2026. Managers file 13F up to 45 days after a quarter ends. 77 managers reported a position.
| Holder | Shares | Change on quarter |
|---|---|---|
| Fmr LLC | 4,993,906 | +1,157,076 |
| BlackRock, Inc. | 4,281,425 | +962,046 |
| Foresite Capital Management IV, LLC | 1,943,682 | 0 |
| Merck & Co., Inc. | 1,666,666 | 0 |
| Foresite Capital Management V, LLC | 1,318,983 | 0 |
| Capital World Investors | 1,175,944 | +32,307 |
| Vanguard Capital Management LLC | 922,707 | -46,724 |
| EcoR1 Capital, LLC | 732,606 | 0 |
| Geode Capital Management, LLC | 556,955 | +283,024 |
| Baker Bros. Advisors LP | 555,555 | 0 |
| Alliancebernstein L.P. | 641,888 | -380,300 |
| Soros Capital Management LLC | 484,672 | 0 |
| StepStone Group LP | 395,340 | 0 |
| Canada Pension Plan Investment Board | 379,024 | 0 |
| State Street Corp | 354,093 | +313,943 |
| Franklin Resources Inc | 350,000 | 0 |
| General Catalyst Group Management, LLC | 305,233 | 0 |
| UBS Group AG | 263,932 | +164,524 |
| Parkman Healthcare Partners LLC | 256,053 | new |
| Charles Schwab Investment Management Inc | 182,105 | +51,026 |
Insiders
6 insiders reported holding 6,393,457 shares in total, about $38.9M at the last price.
| Holder | Shares |
|---|---|
| Lux Venture Partners V, LLCDirector, 10% owner | 2,294,6532,294,653 held indirectly |
| Wolfe JoshDirector, 10% owner | 2,294,6532,294,653 held indirectly |
| Foresite Capital Management IV, LLC10% owner | 1,318,9831,318,983 held indirectly |
| Perlmutter Roger MSee remarks, Director | 284,857284,857 held indirectly |
| Frazier Kenneth CDirector | 111,111 |
| Column Group IV GP, LP10% owner | 89,20089,200 held indirectly |
Questions about EIKN
What does Eikon Therapeutics, Inc. do?
Eikon Therapeutics, Inc. is a company in the Health care sector, listed on NASDAQ as EIKN. Its shares trade on NASDAQ under the ticker EIKN.
What is Eikon Therapeutics, Inc.'s net worth?
Eikon Therapeutics, Inc. has a market value (market cap) of $329.9M at the latest share price. A company's "net worth" usually means this market value or the shareholders' equity on its balance sheet.
When did Eikon Therapeutics, Inc. last report?
Its most recent periodic report is the quarterly report (10-Q) filed on August 13, 2026. It covers the period to June 30, 2026. Its newest filing of any kind is the investor disclosure from October 26, 2026.
When is Eikon Therapeutics, Inc.'s next earnings report?
Eikon Therapeutics, Inc.'s next report was expected around October 20, 2026 and is not on file with the SEC yet.
Similar companies
Compare EIKN with
Follow EIKN
Get an email when Eikon Therapeutics, Inc. files with the SEC: results, executive changes, material agreements and annual reports.
Where the numbers come from
Financial figures are the values Eikon Therapeutics, Inc. tagged in its own SEC filings (XBRL), taken from the latest filing for each period, so restatements replace older figures. Revenue, profit and cash flow are for full fiscal years unless marked as the last twelve months, which is the sum of the four most recent quarters. Where a company reports only the full year, the fourth quarter is the year minus the first three.
Prices are delayed end-of-day market data in the listing currency, and market cap moves with the price. P/E is shown only when earnings per share are positive. Nothing here is investment advice.